Analysis of repeated 24-core saturation prostate biopsy: Inverse association between asymptomatic histological inflammation and prostate cancer detection

Kato, Tomonori; Komiya, Akira; Morii, Akihiro; Iida, Hiroaki; Ito, Takatoshi; Fuse, Hideki

doi:10.3892/ol.2016.4693

Cited by 4 publications

(10 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These detection rates might not be simply compared with each other, as the patient backgrounds including the distribution of MRI scores and PSA are different among the biopsy reports in Japan. However, the CDRs of both any cancer and CSCa by MRUS fusion biopsy technique TB might be greater than the conventional biopsy technique in those reported previous studies . In the present study, CDRs of CSCa per patient were 45.8% in SBx versus 70.2% in MRUS TB ( P < 0.0001).…”

Section: Discussioncontrasting

confidence: 53%

“…Distribution of GS (6/7/8/9/10) was 46/101/35/14/2 in Likert scores 4 and 5 versus 2/4/2/1/0 in Likert score 3 (P < 0.001). MCCL was 8 mm (1)(2)(3)(4)(5)(6)(7)(8)(9)(10)(11)(12)(13)(14)(15)(16)(17)(18)(19) in Likert scores 4 and 5 versus 5 mm (2-15) in Likert score 3 (P < 0.05). The distribution of tumors detected, as well as GS differences in TB and SBx were evaluated.…”

Section: Resultsmentioning

confidence: 94%

“…Table shows the comparison of CDRs in the recent English reports in Japanese patients . The CDRs were available for all eight trials.…”

Section: Resultsmentioning

confidence: 99%

“…1314 Using 24‐core transperineal repeat biopsy, Kato et al . reported that the CDRs were 20.5% (16/78) for all prostate cancer and 12.8% (10/78) for clinically significant cancer . The CDRs of combination cognitive fusion and SBx were 45% and 55% for all prostate cancers, whereas the rates of CSCa were 34.8% and 49%, respectively .…”

Section: Resultsmentioning

confidence: 99%

“…Table 5 shows the comparison of CDRs in the recent English reports in Japanese patients. [13][14][15][16][17][18][19] The CDRs were available for all eight trials. The CDRs of SBx were 47.9% and 45.6% for all prostate cancers, whereas the rates of CSCa were 32.5% and 42%, respectively.…”

Section: Resultsmentioning

confidence: 99%

See 4 more Smart Citations

Magnetic resonance imaging/transrectal ultrasound fusion‐targeted prostate biopsy using three‐dimensional ultrasound‐based organ‐tracking technology: Initial experience in Japan

et al. 2019

View full text Add to dashboard Cite

Objective To evaluate the impact of magnetic resonance imaging/transrectal ultrasound fusion‐targeted prostate biopsy on the diagnosis of clinically significant prostate cancer using real‐time three‐dimensional ultrasound‐based organ‐tracking technology. Methods The present study was a retrospective review of 262 consecutive patients with prostate‐specific antigen of 7.1 ng/mL (interquartile range 4.0–19.8). All patients received pre‐biopsy magnetic resonance imaging and had a suspicious lesion for clinically significant prostate cancer. All patients underwent a combination of systematic biopsy (6 cores) and three‐dimensional ultrasound‐based magnetic resonance imaging/transrectal ultrasound fusion‐targeted biopsy (2 cores). The positive rate of any cancer, positive rate of clinically significant prostate cancer, Gleason score and maximum cancer core length were compared between systematic biopsy versus magnetic resonance imaging/transrectal ultrasound fusion‐targeted prostate biopsy. Results Overall, the positive rate of any cancer per patient was 61% (160/262) in systematic biopsy versus 79% (207/262) in magnetic resonance imaging/transrectal ultrasound fusion‐targeted biopsy (P < 0.0001); and that of clinically significant prostate cancer per patient was 46% (120/262) in systematic biopsy versus 70% (181/262) in magnetic resonance imaging/transrectal ultrasound fusion‐targeted biopsy (P < 0.0001). The positive rate of any cancer per core was 21.7% (330/1523) in systematic biopsy versus 68.6% (406/592) in magnetic resonance imaging/transrectal ultrasound fusion‐targeted biopsy (P < 0.0001), and that of clinically significant prostate cancer per core was 12.7% (193/1423) in systematic biopsy versus 60.3% (357/592) in magnetic resonance imaging/transrectal ultrasound fusion‐targeted biopsy (P < 0.0001). Adding systematic biopsy leads to 13 more cancer cases (5%). The distribution of Gleason score (6/7/8/9/10) was 59/71/23/6/1 in systematic biopsy versus 48/105/36/15/2 in magnetic resonance imaging/transrectal ultrasound fusion‐targeted biopsy (P = 0.005). The maximum cancer core length was 5 mm (0.5–16) in systematic biopsy versus 8 mm (1–19 mm) in magnetic resonance imaging/transrectal ultrasound fusion‐targeted biopsy (P < 0.0001). Conclusions Three‐dimensional ultrasound‐based magnetic resonance imaging/transrectal ultrasound fusion‐targeted biopsy seems to be associated with a higher detection rate of clinically significant prostate cancer, with fewer cores than systematic random biopsy. However, significant cancer can still be detected by the systematic technique only. A combination of systematic biopsy with the targeted biopsy technique would avoid the underdiagnosis of clinically significant prostate cancer.

show abstract

Section: Discussioncontrasting

confidence: 53%

Section: Resultsmentioning

confidence: 94%

“…Table shows the comparison of CDRs in the recent English reports in Japanese patients . The CDRs were available for all eight trials.…”

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 3 more Smart Citations

Magnetic resonance imaging/transrectal ultrasound fusion‐targeted prostate biopsy using three‐dimensional ultrasound‐based organ‐tracking technology: Initial experience in Japan

et al. 2019

View full text Add to dashboard Cite

show abstract

Inflammation on Prostate Needle Biopsy is Associated with Lower Prostate Cancer Risk: A Meta-Analysis

et al. 2018

View full text Add to dashboard Cite

show abstract

Does serum prostate specific antigen levels correlate with the prostatic inflammation in elderly patients without clinically proven prostate cancer?

ÇOLAKEROL

TEMİZ

Boran

et al. 2022

The European Research Journal

View full text Add to dashboard Cite

Objectives: To determine the whether histological prostatic inflammation correlates with serum prostate specific antigen (PSA), free PSA (fPSA) and percent of fPSA (%fPSA) levels in elderly patients without clinically proven prostate cancer. Methods: A total of 115 patients without clinically proven prostate cancer with transrectal prostate biopsy were included in this retrospective study. Patients were divided two main groups as patients with and without histologic prostatic inflammation. A grading of the histological prostatic inflammation was performed and patients with prostatic inflammation were divided into three subgroups. The age, prostate volume, serum PSA, fPSA and %fPSA levels were compared between patients with and without prostatic inflammation. Correlation between the parameters and grade of prostatic inflammation was also investigated. Results: Serum PSA and %fPSA levels were significantly higher in men with histologically proven prostatic inflammation (15.47 ± 15.28 ng/mL vs. 11.67 ± 8.12 ng/mL; p = 0.002 and 19.8 ± 0.7 vs. 15.79 ± 0.9; p = 0.01, respectively). The mean serum PSA levels were significantly different among the subgroups (p = 0.02) and prostatic inflammation correlated positively with the PSA levels (r = 0.320, p < 0.001). Conclusions: Our findings suggested that reporting the grade of prostatic inflammation in elderly patients may help avoiding unnecessary repeat biopsies if elevated serum PSA level is the only indication for initial prostate biopsy.

show abstract

Analysis of repeated 24-core saturation prostate biopsy: Inverse association between asymptomatic histological inflammation and prostate cancer detection

Cited by 4 publications

References 43 publications

Magnetic resonance imaging/transrectal ultrasound fusion‐targeted prostate biopsy using three‐dimensional ultrasound‐based organ‐tracking technology: Initial experience in Japan

Magnetic resonance imaging/transrectal ultrasound fusion‐targeted prostate biopsy using three‐dimensional ultrasound‐based organ‐tracking technology: Initial experience in Japan

Inflammation on Prostate Needle Biopsy is Associated with Lower Prostate Cancer Risk: A Meta-Analysis

Does serum prostate specific antigen levels correlate with the prostatic inflammation in elderly patients without clinically proven prostate cancer?

Contact Info

Product

Resources

About